Recursion Pharmaceuticals, Inc. (RXRX) on Decifer

Why it ranks here

• Sales are growing about 33% a year, faster than 83 in 100 companies we measure.
• It costs about 28 times its yearly sales; the middle of its industry is 10. Cheaper than 10 in 100 companies we measure, against their own industries.

The current read

The evidence on RXRX lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Read the full RXRX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.